NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. - Wikidata - awgldk - TriplyDB

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

http://www.wikidata.org/entity/Q34102089

about

Nelarabine in the treatment of refractory T-cell malignancies Assessment of bone marrow involvement in patients with lymphoma: report on a consensus meeting of the Korean Society of Hematology Lymphoma Working Party Pruritus Reduction with Systemic Anti-lymphoma Treatments in Patients with Cutaneous T Cell Lymphoma: A Narrative Review Nodular fasciitis in the axillary tail of the breast.Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149.Cyclosporine, prednisone, and high-dose immunoglobulin treatment of angioimmunoblastic T-cell lymphoma refractory to prior CHOP or CHOP-like regimen Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.Discrepancies in Lymphoma Diagnosis Over the Years: A 13-Year Experience in a Tertiary Center Non-Hodgkin Lymphoma of the Liver: A US Population-based Analysis.Clinical analysis of 42 cases of EBV-positive mature T/NK-cell neoplasms.ASCO Provisional Clinical Opinion: Chronic Hepatitis B Virus Infection in Patients Receiving Cytotoxic Chemotherapy for Treatment of Malignant Diseases Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.Pharmaceutical follow-up for patients on rituximab therapy for non-Hodgkin lymphoma: what is the evidence?HIV-associated primary effusion lymphoma presenting as a paracardial mass.Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment.VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.Hepatitis B reactivation and rituximab in the oncology practice.An argument for the universal prophylaxis of hepatitis B infection in patients receiving rituximab: a 7-year institutional experience of hepatitis screening Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients.The use of Yttrium-90 Ibritumomab Tiuxetan ((90)Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation.Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamics Regression of Advanced Gastric MALT Lymphoma after the Eradication of Helicobacter pylori Recurrent PET FDG Uptake after Sequential Chemotherapy and Radiation Therapy for DLBCL of the Tibia: A Case Report and Review of the Literature Kimura Disease Simulating Hodgkin's Lymphoma on (18)F FDG PET-CT: Report of a Case.Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era.Prognostic and Clinicopathological Value of Survivin in Diffuse Large B-cell Lymphoma: A Meta-Analysis Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare.Synchronous bilateral breast carcinoma and axillary non-hodgkin lymphoma: a case report and review of the literature Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy.Discordant bone marrow involvement in non-Hodgkin lymphoma.The High Effect of Chemomobilization with High-Dose Etopside + Granulocyte-Colony Stimulating Factor in Autologous Hematopoietic Peripheral Blood Stem Cell Transplantation: A Single Center Experience.Stage IAE Follicular Lymphoma of the Breast: Case Report and Review of the Literature Asymptomatic cardiac toxicity in long-term cancer survivors: defining the population and recommendations for surveillance.High-Intensity Chemotherapy is Associated with Better Prognosis in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma: A 10-Year Single-Center Retrospective Cohort Study.Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.Primary Gastrointestinal Lymphoma: A Retrospective Multicenter Clinical Study of 415 Cases in Chinese Province of Guangdong and a Systematic Review Containing 5075 Chinese Patients.Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009.Extended Course and Increased Dose of Initial Chemotherapy for Extranodal Nasal Type Natural Killer/T (NK/T)-Cell Lymphoma in Patients <60 Years Old: A Single-Center Retrospective Cohort Study.

P2860

Q24569660-155D2A40-B1E1-4912-88A0-78CE09C23253 Q28073223-3A7619A4-4A6C-44B9-A42F-F8E8C0875B21 Q28075343-F754A8DD-EEB5-46A9-AE5C-7700390CC5A2 Q30424689-F3F6EE2F-59E6-4228-BA33-068C3C7CDC07 Q33433689-D4D6FD42-CF03-4420-8894-0A2D563C0455 Q33574969-B14594F6-AD88-47F9-8A04-BAE6031C92EC Q33586239-A1E0687D-A129-4F34-B5D7-3BA041A21658 Q33747827-FF8172FC-268E-4B24-9442-C1BBB96EB225 Q33805254-A0E91157-F1AF-412B-A344-000BF124EDBE Q33846399-71612857-C09D-4B27-A5F5-01D9834C03F4 Q33978916-01834C34-5184-42D6-97FB-B4CE4146408F Q34052075-07EFC7B2-8BF6-4CF7-93EC-93076FF194E2 Q34310845-9D92F841-1DE2-4E05-AFD8-846CE1AF5BB4 Q34757945-01FDB938-50EB-45AC-9718-E81CFCE934A1 Q35139256-D4594C5A-3937-4F77-ADC0-CB95CD3EF30B Q35153794-96CFA851-DE98-4E9D-A3C7-35F2772FF197 Q35285011-B46C9212-2B3B-4296-8DDF-89ED7EA95B00 Q35583718-9708B48C-C628-4ABE-ABB3-965B381609FD Q35584844-053AFAE1-04C9-463A-A25D-666DA1929C1B Q35755896-75FFB012-134C-40BE-9F06-45D654BEAD0B Q35867299-3E2003AB-EFAF-4DC0-9B74-2297A2702A39 Q35919697-025F9F25-8CD3-454E-8A2B-FF4CD13D0111 Q35931248-A5AA9371-5286-4AAC-BEBC-BC310DB0CF79 Q35952479-2B077D43-87DC-4B60-BE85-48CD241B8947 Q36064584-0537E91E-4205-49F3-AAE1-891BCF4B66CF Q36194582-436E1B41-6507-4B35-84FB-47E74E398D03 Q36194805-E4A91FCF-E934-489C-A940-4022DEA93A6A Q36210598-B03256AA-9AA0-4B20-96A8-5AB556DC0FAD Q36289360-97E573DD-2733-48AB-B41C-A840A2DCA9B4 Q36354265-359C759A-889C-4213-8F84-9B7EB12208EF Q36528137-8F3F4AB1-601E-41BD-A958-C6A30401EF5A Q36622212-A83D0A53-030B-4960-9E02-B864512AF527 Q36751217-0988279B-0F2A-4338-8821-F177A24BEB59 Q36877113-8B41F41B-DBB2-48C3-883C-863468D29BF7 Q36939536-160FF43B-C712-4CF1-97DB-9A00F54F614C Q37020999-82B1CDB5-DFA9-480E-8E57-3690950C49D0 Q37178611-B1940C01-222E-4C0F-80E3-1E0F9D96B545 Q37328664-BFF85352-4A7F-494D-AE4D-6ECAA6ADA9C3 Q37379370-7C9F94F9-36B7-4906-B8EA-00BA8C8C586A Q37425998-E5D9E466-EC48-4AEE-AC72-083A7F0C1664

P2860

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

http://www.wikidata.org/entity/Q34102089

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

@ast

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

@en

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

@nl

type

label

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

@ast

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

@en

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

@nl

prefLabel

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

@ast

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

@en

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

@nl

P1433

Q34102089-86F092BF-2116-419E-8CEE-0D16EE1FD6DD

P1476

Q34102089-3D166980-2935-4540-A879-E09271837209

P2093

Q34102089-0F3FA939-234D-4898-B856-8CAB7C60A3EA

Q34102089-11AC4437-16EF-47EB-8158-61F27A60E54C

Q34102089-11D8AF71-C178-44B9-9405-B5AC5E0E88D4

Q34102089-2A74C51B-31EA-43AB-8D93-DB6BE340E28B

Q34102089-3DC24F9D-6233-4F0A-B0A9-1D06F0578E96

Q34102089-4230BEB3-3B98-427C-8CD0-260844645636

Q34102089-46B0AE1C-9779-4D63-AB3E-AC702E10C554

Q34102089-5C1FF66B-69C5-4597-AC63-241BBA93F47D

Q34102089-6D3CFA52-CBEA-4D8B-9738-214F9F1FB6E5

Q34102089-72AA1EEA-BA95-4DC4-91A8-6034A2FB3EFA

P304

Q34102089-435F94A0-5A6F-417B-AD31-5D75FA0AD4CF

P31

Q34102089-734630C5-C7DB-49DB-AA0E-B8296D7DF123

P356

Q34102089-81E8A2FA-CB29-48C6-AE49-BB86D1402565

P433

Q34102089-F81C1914-CDAC-4327-9A29-9EBDC166F246

P478

Q34102089-ABBC0788-A332-4294-8DEE-E2CCE29E15EE

P50

Q34102089-1E2F4D73-5B52-4521-B64F-0476FCFC6563

Q34102089-AE7B5B0D-3294-4074-835A-6D20C6A832CD

Q34102089-F7090BEF-FB54-4E3E-800C-524D1371835C

P577

Q34102089-417549B9-E171-4690-B004-D7A060B6B42C

P698

Q34102089-EF5530E7-18C6-4974-9EA3-B6E16D7D54BC

P356

JNCCN.2010.0021

P1433

Journal of the National Comprehensive Cancer Network

P1476

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

@en

P2093

Andres Forero

http://www.w3.org/2001/XMLSchema#string

Andrew D Zelenetz

http://www.w3.org/2001/XMLSchema#string

Ann S Lacasce

http://www.w3.org/2001/XMLSchema#string

Auyporn Nademanee

http://www.w3.org/2001/XMLSchema#string

C Babis Andreadis

http://www.w3.org/2001/XMLSchema#string

Furhan Yunus

http://www.w3.org/2001/XMLSchema#string

Jeremy S Abramson

http://www.w3.org/2001/XMLSchema#string

Joachim Yahalom

http://www.w3.org/2001/XMLSchema#string

Jon P Gockerman

http://www.w3.org/2001/XMLSchema#string

Leo I Gordon

http://www.w3.org/2001/XMLSchema#string

P304

288-334

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.6004/JNCCN.2010.0021

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

William G Wierda

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20202462

http://www.w3.org/2001/XMLSchema#string